RaySearch Laboratories AB Class B ( (RSLBF) ) has released its Q1 earnings. Here is a breakdown of the information RaySearch Laboratories AB Class B presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
RaySearch Laboratories AB is a Swedish medical technology company specializing in innovative software solutions for cancer treatment, including treatment planning and oncology information systems. In the first quarter of 2025, RaySearch Laboratories reported a 29% increase in net sales compared to the same period last year, reaching SEK 331.7 million. The company’s operating profit also saw a significant rise to SEK 74.8 million, driven by a 39.4% increase in license revenue. Notably, the order intake surged by 71.7%, amounting to SEK 409.6 million, highlighting strong market demand. Key achievements during the quarter included a major order from Heyou Hospital in China and the release of a new version of their RayStation software. Looking forward, RaySearch remains optimistic about continued growth and aims to maintain a minimum operating margin of 25% by 2026, reflecting a strong financial position and strategic focus on innovation.